Cargando…

Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium

Since its emergence in 2019, circulating populations of the new coronavirus (CoV) continuously acquired genetic diversity. At the end of 2020, a variant named 20I/501Y.V1 (lineage B.1.1.7) emerged and replaced other circulating strains in several regions. This phenomenon has been poorly associated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Touret, Franck, Luciani, Léa, Baronti, Cécile, Cochin, Maxime, Driouich, Jean-Sélim, Gilles, Magali, Thirion, Laurence, Nougairède, Antoine, de Lamballerie, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Observation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406299/ https://www.ncbi.nlm.nih.gov/pubmed/34225487 http://dx.doi.org/10.1128/mBio.00850-21

Ejemplares similares

The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model
por: Cochin, Maxime, et al.
Publicado: (2022)

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
por: Tang, Haijun, et al.
Publicado: (2021)

Corrigendum: Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
por: Tang, Haijun, et al.
Publicado: (2021)

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
por: Liu, Haolin, et al.
Publicado: (2021)

Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets
por: Riddell, Shane, et al.
Publicado: (2021)

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)
por: Weiss, Anne, et al.
Publicado: (2021)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

Possible Role of Accessory Proteins in the Viral Replication for the 20I/501Y.V1 (B.1.1.7) SARS CoV-2 Variant
por: Nyayanit, Dimpal A., et al.
Publicado: (2021)

Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model
por: Cochin, Maxime, et al.
Publicado: (2022)

Increased elastase sensitivity and decreased intramolecular interactions in the more transmissible 501Y.V1 and 501Y.V2 SARS-CoV-2 variants’ spike protein–an in silico analysis
por: Pokhrel, Suman, et al.
Publicado: (2021)

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2
por: Liu, Haolin, et al.
Publicado: (2021)

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2
por: Touret, Franck, et al.
Publicado: (2021)

The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients
por: Teyssou, Elisa, et al.
Publicado: (2021)

Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2
por: Saade, Carla, et al.
Publicado: (2021)

In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2–Spike RBD Interface
por: Villoutreix, Bruno O., et al.
Publicado: (2021)

Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021
por: Gaymard, Alexandre, et al.
Publicado: (2021)

501Y.V2 spike protein resists the neutralizing antibody in atomistic simulations
por: Ngo, Son Tung
Publicado: (2022)

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Thermodynamics and kinetics in antibody resistance of the 501Y.V2 SARS-CoV-2 variant
por: Ngo, Son Tung, et al.
Publicado: (2021)

Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK
por: Tang, Julian W., et al.
Publicado: (2021)

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
por: Touret, Franck, et al.
Publicado: (2022)

Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques
por: Li, Rong, et al.
Publicado: (2021)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2021)

A simple reverse genetics method to generate recombinant coronaviruses
por: Mélade, Julien, et al.
Publicado: (2022)

Detection of SARS-CoV-2 variant 501Y.V2 in Comoros Islands in January 2021
por: N. Agoti, Charles, et al.
Publicado: (2021)

Preliminary data on severe SARS-CoV-2 infection caused by the 501Y.V2 variant
por: Louis, Guillaume, et al.
Publicado: (2021)

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
por: Touret, Franck, et al.
Publicado: (2022)

Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy
por: Novazzi, Federica, et al.
Publicado: (2021)

Genome Sequence of a SARS-CoV-2 P.1 Variant of Concern (20J/501Y.V3) from Bangladesh
por: Sarkar, M. Murshed Hasan, et al.
Publicado: (2021)

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2
por: Huang, Baoying, et al.
Publicado: (2021)

Imported SARS-CoV-2 V501Y.V2 variant (B.1.351) detected in travelers from South Africa and Tanzania to India
por: Yadav, Pragya D., et al.
Publicado: (2021)

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
por: Li, Qianqian, et al.
Publicado: (2021)

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
por: Wibmer, Constantinos Kurt, et al.
Publicado: (2021)

Efficiency of transmission-based precautions (TBPs) against SARS-CoV-2 501Y.V2 variant transmissibility in the ICU
por: Schortgen, Frédérique, et al.
Publicado: (2021)

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2
por: Driouich, Jean-Sélim, et al.
Publicado: (2022)

Outbreak of SARS-CoV-2 Lineage 20I/501Y.V1 in a Nursing Home Underlines the Crucial Role of Vaccination in Both Residents and Staff
por: Orsi, Andrea, et al.
Publicado: (2021)

Complete Coding Sequences of Two Dengue Virus Type 2 Strains Isolated from an Outbreak in Burkina Faso in 2016
por: Baronti, Cécile, et al.
Publicado: (2017)

Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch
por: O'Toole, Áine, et al.
Publicado: (2021)

Evaluation of formulations to improve SARS-CoV-2 viability and thermostability after lyophilisation
por: Baronti, C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_93ho4ra0uqoqiu3b9quq9nto67